• Alterity Therapeutics highlighted new conference presentations that it says support advancing ATH434 into a Phase 3 trial in multiple system atrophy, with results already presented at three medical meetings.
• The update points to Phase 2 findings that indicated a statistically significant slowing of disease progression, positioning the program as a potential disease-modifying approach in a condition with no approved therapy.
• Separate imaging research presented at an MRI conference described an approach that could help identify patients earlier and track disease-related brain changes over time, which Alterity is using to shape Phase 3 trial design.
• An end-of-Phase 2 meeting with the FDA is targeted for mid-2026 to confirm the Phase 3 path forward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.